ATP6V1C1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human cerebella tissue and Human cerebrum tissue lysates, Primary antibody: P10136(ATP6V1C1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10136(ATP6V1C1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10136(ATP6V1C1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

The ATP6V1C1 antibody is a research tool targeting the ATP6V1C1 subunit, a critical component of vacuolar-type H+-ATPase (V-ATPase). V-ATPase is a multisubunit proton pump responsible for acidifying intracellular compartments like lysosomes and secretory vesicles, as well as regulating extracellular pH in specialized cells. The ATP6V1C1 subunit, part of the V1 domain, plays a structural and regulatory role in ATP hydrolysis and proton translocation. Dysregulation of ATP6V1C1 is linked to diseases including cancer, osteoporosis, and renal tubular acidosis, as aberrant V-ATPase activity affects processes like protein degradation, bone resorption, and tumor microenvironment modulation.

ATP6V1C1 antibodies are widely used in studies exploring V-ATPase's role in cellular physiology and pathology. They enable detection of protein expression, localization, and post-translational modifications via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific applications include investigating ATP6V1C1 overexpression in cancer cells, where it promotes metastasis by enhancing extracellular acidification, or studying its contribution to osteoclast function in bone remodeling. Commercial antibodies vary in clonality (monoclonal/polyclonal), species reactivity (human, mouse, rat), and validation standards. Researchers must verify specificity using knockout controls, as cross-reactivity with other V-ATPase subunits may occur. These antibodies also support drug discovery targeting V-ATPase in diseases like osteoporosis or chemotherapy resistance.